Your browser doesn't support javascript.
loading
Noninferiority of Local Control and Comparable Toxicity of Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Breast Cancer: 5-Year Results of the IMRT-MC2 Phase III Trial.
Forster, Tobias; Köhler, Clara; Dorn, Melissa; Häfner, Matthias Felix; Arians, Nathalie; König, Laila; Harrabi, Semi Ben; Schlampp, Ingmar; Weykamp, Fabian; Meixner, Eva; Lang, Kristin; Heinrich, Vanessa; Weidner, Nicola; Hüsing, Johannes; Wallwiener, Markus; Golatta, Michael; Hennigs, André; Heil, Jörg; Hof, Holger; Krug, David; Debus, Jürgen; Hörner-Rieber, Juliane.
Affiliation
  • Forster T; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany.
  • Köhler C; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  • Dorn M; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  • Häfner MF; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany.
  • Arians N; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany.
  • König L; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany.
  • Harrabi SB; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany.
  • Schlampp I; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany.
  • Weykamp F; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany.
  • Meixner E; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany.
  • Lang K; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany.
  • Heinrich V; Department of Radiation Oncology, Eberhard-Karls-University Tuebingen, Tuebingen, Germany.
  • Weidner N; Department of Radiation Oncology, Eberhard-Karls-University Tuebingen, Tuebingen, Germany.
  • Hüsing J; Division of Biostatistics, Coordination Centre for Clinical Trials, University of Heidelberg, Heidelberg, Germany.
  • Wallwiener M; Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.
  • Golatta M; Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.
  • Hennigs A; Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.
  • Heil J; Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.
  • Hof H; Strahlentherapie Rhein-Pfalz, Neustadt, Germany.
  • Krug D; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Department of Radiation Oncology, University Hospital Schleswig Holstein, Kiel, Germany.
  • Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Ge
  • Hörner-Rieber J; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Ge
Int J Radiat Oncol Biol Phys ; 117(4): 857-868, 2023 Nov 15.
Article in En | MEDLINE | ID: mdl-37244626
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2023 Document type: Article Affiliation country: Alemania
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2023 Document type: Article Affiliation country: Alemania